A possible new role for Aβ in vascular and inflammatory dysfunction in Alzheimer's disease

Thrombosis Research

Volumn 141, Issue , 2016, Pages S59-S61

  Zamolodchikov, Daria ^a   Strickland, Sidney ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; beta amyloid; contact activation system; factor XII; fibrin(ogen)

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; FIBRIN; FIBRINOGEN; HIGH MOLECULAR WEIGHT KININOGEN; PLASMA KALLIKREIN; PREKALLIKREIN; THROMBIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; CHRONIC INFLAMMATION; FIBRIN CLOT; FIBRIN DEPOSITION; FIBRIN FORMATION; HUMAN; KALLIKREIN KININ SYSTEM; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; VASCULAR DISEASE; ANIMAL; BLOOD; COMPLICATION; IMMUNOLOGY; INFLAMMATION; PATHOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOOD COAGULATION; FACTOR XII; FIBRINOGEN; HUMANS; INFLAMMATION;

EID: 84989937227     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(16)30367-X     Document Type: Article

References (45)

1. 1 Miyakawa, T, Uehara, Y, Desaki, J, Kimura, T, Kuramoto, R, Morphological changes of microvessels in the brain with Alzheimer's disease. The Japanese journal of psychiatry and neurology 42 (1988), 819–824.
2. 2 Kalaria, RN, Ballard, C, Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer disease and associated disorders 13:Suppl 3 (1999), S115–S123.
3. 3 Kalaria, RN, The role of cerebral ischemia in Alzheimer's disease. Neurobiology of aging 21 (2000), 321–330.
4. 4 Farkas, E, Luiten, PG, Cerebral microvascular pathology in aging and Alzheimer's disease. Progress in neurobiology 64 (2001), 575–611.
5. 5 Cortes-Canteli, M, Zamolodchikov, D, Ahn, HJ, Strickland, S, Norris, EH, Fibrinogen and altered hemostasis in Alzheimer's disease. J Alzheimers Dis 32 (2012), 599–608.
6. 6 Brundel, M, de Bresser, J, van Dillen, JJ, Kappelle, LJ, Biessels, GJ, Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 32 (2012), 425–436.
7. 7 van Rooden, S, Goos, JD, van Opstal, AM, Versluis, MJ, Webb, AG, Blauw, GJ, et al. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 270 (2014), 205–211.
8. 8 Chi, NF, Chien, LN, Ku, HL, Hu, CJ, Chiou, HY, Alzheimer disease and risk of stroke: a population-based cohort study. Neurology 80 (2013), 705–711.
9. 9 Cortes-Canteli, M, Paul, J, Norris, EH, Bronstein, R, Ahn, HJ, Zamolodchikov, D, et al. Fibrinogen and beta-Amyloid Association Alters Thrombosis and Fibrinolysis: a Possible Contributing Factor to Alzheimer's Disease. Neuron 66 (2010), 695–709.
10. 10 Jarre, A, Gowert, NS, Donner, L, Munzer, P, Klier, M, Borst, O, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease. Cellular signalling 26 (2014), 2040–2050.
11. 11 Barber, M, Tait, RC, Scott, J, Rumley, A, Lowe, GD, Stott, DJ, Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J Thromb Haemost 2 (2004), 1873–1878.
12. 12 Ratner, J, Rosenberg, G, Kral, VA, Engelsmann, F, Anticoagulant therapy for senile dementia. J Am Geriatr Soc 20 (1972), 556–559.
13. 13 Walsh, AC, Walsh, BH, Melaney, C, Senile-presenile dementia: follow-up data on an effective psychotherapy-anticoagulant regimen. J Am Geriatr Soc 26 (1978), 467–470.
14. 14 Walsh, AC, Anticoagulant therapy for Alzheimer's disease. J Neuropsychiatry Clin Neurosci 8 (1996), 361–362.
15. 15 Bergamaschini, L, Rossi, E, Storini, C, Pizzimenti, S, Distaso, M, Perego, C, et al. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24 (2004), 4181–4186.
16. 16 Timmer, NM, van Dijk, L, van der Zee, CE, Kiliaan, A, de Waal, RM, Verbeek, MM, Enoxaparin treatment administered at both early and late stages of amyloid beta deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Abeta levels. Neurobiol Dis 40 (2010), 340–347.
17. 17 Wyss-Coray, T, Rogers, J, Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med, 2, 2012, a006346.
18. 18 Wyss-Coray, T, Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 12 (2006), 1005–1015.
19. 19 Hardy, J, Selkoe, DJ, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
20. 20 Tanzi, RE, Bertram, L, Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120 (2005), 545–555.
21. 21 Ahn, HJ, Zamolodchikov, D, Cortes-Canteli, M, Norris, EH, Glickman, JF, Strickland, S, Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci U S A 107 (2010), 21812–21817.
22. 22 Zamolodchikov, D, Strickland, S, Abeta delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 119 (2012), 3342–3351.
23. 23 Hultman, K, Strickland, S, Norris, EH, The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab 33 (2013), 1251–1258.
24. 24 Klohs, J, Baltes, C, Princz-Kranz, F, Ratering, D, Nitsch, RM, Knuesel, I, et al. Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAbeta mice. J Neurosci 32 (2012), 1705–1713.
25. 25 Adams, RA, Passino, M, Sachs, BD, Nuriel, T, Akassoglou, K, Fibrin mechanisms and functions in nervous system pathology. Mol Interv 4 (2004), 163–176.
26. 26 Davalos, D, Akassoglou, K, Fibrinogen as a key regulator of inflammation in disease. Sem Immunopathol 34 (2012), 43–62.
27. 27 Nishimura, N, Schaffer, CB, Big effects from tiny vessels: imaging the impact of microvascular clots and hemorrhages on the brain. Stroke 44 (2013), S90–S92.
28. 28 Cortes-Canteli, M, Mattei, L, Richards, AT, Norris, EH, Strickland, S, Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiol Aging 36 (2015), 608–617.
29. 29 Paul, J, Strickland, S, Melchor, JP, Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204 (2007), 1999–2008.
30. 30 Ahn, HJ, Glickman, JF, Poon, KL, Zamolodchikov, D, Jno-Charles, OC, Norris, EH, et al. A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med 211 (2014), 1049–1062.
31. 31 Pimentel-Coelho, PM, Rivest, S, The early contribution of cerebrovascular factors to the pathogenesis of Alzheimer's disease. Eur J Neurosci 35 (2012), 1917–1937.
32. 32 Takeda, S, Sato, N, Morishita, R, Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front Aging Neurosci, 6, 2014, 171.
33. 33 Adams, RA, Bauer, J, Flick, MJ, Sikorski, SL, Nuriel, T, Lassmann, H, et al. The fibrin-derived gamma377–395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J Exp Med 204 (2007), 571–582.
34. 34 Schachtrup, C, Lu, P, Jones, LL, Lee, JK, Lu, J, Sachs, BD, et al. Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor. Proc Natl Acad Sci U S A 104 (2007), 11814–11819.
35. 35 Schachtrup, C, Ryu, JK, Helmrick, MJ, Vagena, E, Galanakis, DK, Degen, JL, et al. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J Neurosci 30 (2010), 5843–5854.
36. 36 Renné, T, Schmaier, AH, Nickel, KF, Blomback, M, Maas, C, In vivo roles of factor XII. Blood 120 (2012), 4296–4303.
37. 37 Shibayama, Y, Joseph, K, Nakazawa, Y, Ghebreihiwet, B, Peerschke, EI, Kaplan, AP, Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol 90 (1999), 89–99.
38. 38 Maas, C, Govers-Riemslag, JW, Bouma, B, Schiks, B, Hazenberg, BP, Lokhorst, HM, et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118 (2008), 3208–3218.
39. 39 Bergamaschini, L, Donarini, C, Gobbo, G, Parnetti, L, Gallai, V, Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 122 (2001), 1971–1983.
40. 40 Zamolodchikov, D, Chen, ZL, Conti, BA, Renne, T, Strickland, S, Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A 112 (2015), 4068–4073.
41. 41 Musiek, ES, Holtzman, DM, Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Opin Neurol 25 (2012), 715–720.
42. 42 Zamolodchikov, D, Renne, T, Strickland, S, The Alzheimer's disease peptide Abeta promotes thrombin generation through activation of coagulation factor XII. J Thromb Haemost, 2015 [Epub ahead of print].
43. 43 Cutler, P, Akuffo, EL, Bodnar, WM, Briggs, DM, Davis, JB, Debouck, CM, et al. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: Two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clinical applications 2 (2008), 467–477.
44. 44 Muenchhoff, J, Poljak, A, Song, F, Raftery, M, Brodaty, H, Duncan, M, et al. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts. J Alzheimers Dis 43 (2015), 1355–1373.
45. 45 Merkulov, S, Zhang, WM, Komar, AA, Schmaier, AH, Barnes, E, Zhou, Y, et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111 (2008), 1274–1281.